PPD Recognized for Exceptional Quality of Collaboration with Clinical Research Sites

April 25, 2019 13:00 UTC

WILMINGTON, N.C.--(BUSINESS WIRE)-- Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), was named the winner of the CRO Quality Award from the Association of Clinical Research Professionals (ACRP) and The Avoca Group during the recent ACRP annual conference in Nashville, Tennessee.

PPD’s selection was based on The Avoca Group’s independent research with investigator sites, which recognized PPD’s industry leadership on quality outcomes in the design, execution and oversight of clinical trials, as well as strong communication and partnership skills.

PPD has strategic relationships with sites and site networks across the globe, providing access to industry-leading numbers of patients and high-performing sites. Leveraging these partnerships allows for efficient study startup and execution.

“The strength of our relationships with investigator sites is a critical factor in delivering on our promise of quality execution and on-time delivery for our clients,” said David Johnston, Ph.D., executive vice president of clinical development for PPD. “This accolade reflects our steadfast commitment to collaborate effectively with our partners at clinical research sites to help our clients bring high-quality, life-changing medicines to patients.”

The Avoca Group, which conducted its research over an eight-week period in early 2019, said site personnel rated PPD highly for responsive, high-quality communication, clinical research associates with strong knowledge of the study protocol and several aspects of study execution, including reliability of clinical supplies, ease of use of the electronic data capture (EDC) system and study closeout.

“We congratulate PPD for being recognized by site-based clinical researchers for its ability to work effectively with investigative sites,” says Jim Kremidas, ACRP’s executive director. “Recognition of quality partners in the clinical trial community, such as PPD, greatly supports our mission to promote excellence in clinical research.”

Patricia Leuchten, CEO of The Avoca Group, added: “Congratulations to PPD and its clinical teams for being recognized by investigative sites for their dedication to achieving quality outcomes. This award is a testament to PPD’s commitment to delivering excellence in clinical research.”

Located in more than 70 countries, ACRP’s 13,000 members work in a variety of practice settings, roles and specialty areas, with a wide range of experience in clinical research. With 20 years of experience providing research and consulting services, The Avoca Group merges deep institutional knowledge in the foundations of good clinical practice with leadership in regulatory compliance, quality management and clinical operations across the evolving clinical trials landscape.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 48 countries and more than 21,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.

 

Contacts

Media:
Randy Buckwalter
+1 919 456 4425
randy.buckwalter@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

 
 

Source: PPD

Back to news